Takeda Pharmaceutical Company Limited (TAK)

NYSE: TAK · Real-Time Price · USD
15.10
-0.24 (-1.56%)
Sep 12, 2025, 4:00 PM EDT - Market closed
-1.56%
Market Cap47.48B
Revenue (ttm)31.05B
Net Income (ttm)949.04M
Shares Out 1.56B
EPS (ttm)0.59
PE Ratio50.02
Forward PEn/a
Dividend$0.54 (3.60%)
Ex-Dividend DateMar 31, 2025
Volume2,820,537
Open15.20
Previous Close15.34
Day's Range15.03 - 15.20
52-Week Range12.80 - 15.69
Beta0.27
Analystsn/a
Price Targetn/a
Earnings DateOct 30, 2025

About TAK

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, A... [Read more]

Sector Healthcare
Founded 1781
Employees 47,455
Stock Exchange NYSE
Ticker Symbol TAK
Full Company Profile

Financial Performance

In 2024, Takeda Pharmaceutical's revenue was 4.58 trillion, an increase of 7.45% compared to the previous year's 4.26 trillion. Earnings were 107.93 billion, a decrease of -25.08%.

Financial numbers in JPY Financial Statements

News

Takeda Appoints Rhonda Pacheco President of the U.S. Business Unit

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that Rhonda Pacheco, most recently group vice president of U.S. Cardiometabolic Health at Eli Lilly, will join Takeda, eff...

2 days ago - Business Wire

Takeda Pharmaceutical Company Limited (TAK) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Takeda Pharmaceutical Company Limited (NYSE:TAK) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 3:20 PM EDT Company Participants Milano Furuta - CFO & Director Conference C...

5 days ago - Seeking Alpha

Takeda Pharmaceutical Company Limited (TAK) Oveporexton (TAK-861) Investor Call On Phase 3 Narcolepsy Type 1 Data Presented At World Sleep 2025 (Transcript)

Takeda Pharmaceutical Company Limited (NYSE:TAK) Oveporexton (TAK-861) Investor Call on Phase 3 Narcolepsy Type 1 Data Presented at World Sleep 2025 Company Participants Christopher David O'Reilly - ...

5 days ago - Seeking Alpha

Takeda Presents Orexin Data from Landmark Oveporexton (TAK-861) Phase 3 Program in Narcolepsy Type 1 at World Sleep 2025

SINGAPORE & OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) will present data from two global Phase 3 double-blind, placebo-controlled studies of oveporexton (TAK-861)1, a...

6 days ago - Business Wire

U.S. FDA Approves Expanded Indication for VONVENDI® [von Willebrand factor (Recombinant)] for Adults and Children with Von Willebrand Disease

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Applicatio...

8 days ago - Business Wire

What's Going On With Takeda Stock On Friday?

On Friday, Takeda Pharmaceutical Co Ltd's TAK stock wobbled after touching as low as $14.53 during the premarket session, before bouncing back to about $15.47 at last check Friday.

22 days ago - Benzinga

Japan's Takeda weighs India for global trials to speed up drug launches

Japanese drugmaker Takeda Pharmaceutical is exploring the option of conducting global clinical trials in India to accelerate the launch of its innovative drugs in the world's most populous nation, its...

24 days ago - Reuters

Cosmo and Takeda Renew Strategic Manufacturing Agreement for Global Supply of Oral Treatment for Ulcerative Colitis

Dublin, Ireland--(Newsfile Corp. - August 8, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN), a global leader in AI-driven healthcare and specialty pharmaceuticals, today announced the renewal of its m...

5 weeks ago - Newsfile Corp

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo...

6 weeks ago - CNBC Television

President Trump demands drugmakers slash prices within 60 days

CNBC's Joe Kernen reports on the latest news.

6 weeks ago - CNBC Television

Takeda Pharma Maintains Outlook Even As Vyvanse Generics Hit Sales

Takeda Pharmaceutical Company Limited TAK posted a strong first-quarter performance for 2025 on Wednesday, with a net profit of 124.2 billion Japanese yen (approximately $834.08 million), reflecting a...

6 weeks ago - Benzinga

Takeda Pharmaceutical Company Limited (TAK) Q1 FY2025 Earnings Call Transcript

Takeda Pharmaceutical Company Limited (NYSE:TAK) Q1 FY2025 Earnings Call July 30, 2025 6:00 AM ET Company Participants Furuta - Corporate Participant O'Reilly - Corporate Participant Plump - Corporat...

6 weeks ago - Seeking Alpha

Takeda Announces First-Quarter FY2025 Results With Significant Late-Stage Pipeline Progression

OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the first quarter of fiscal year 2025 (three months ended June 30, 2025), with generic erosion of VYVAN...

6 weeks ago - Business Wire

Takeda Receives FDA 510(k) Clearance for HyHubTM and HyHubTM Duo Devices to Simplify HYQVIA® Administration

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for HyHubTM and HyHubTM Duo, ...

7 weeks ago - Business Wire

Takeda: Positioned To Tackle Future Clinical Demand In A Highly Regulated Sector

In my followup on Takeda Pharmaceutical Co (TAK), I am reaffirming my buy rating from March. Clinical demand in multiple areas, along with an active drug pipeline, could keep driving the top-line desp...

2 months ago - Seeking Alpha

Takeda Announces Positive Results from Two Pivotal Phase 3 Studies of Oveporexton (TAK-861) in Narcolepsy Type 1

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that all primary and secondary endpoints were met in two Phase 3 randomized, double-blind, placebo-controll...

2 months ago - Business Wire

Takeda Announces U.S. FDA Approval of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content1

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved GAMMAGARD LIQUID ERC [immune globulin infusio...

2 months ago - Business Wire

Takeda Announces New Assignments of Directors

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) has announced new assignments of directors, determined at the Board of Directors meeting, following the 149th Annual Meet...

2 months ago - Business Wire

European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Newly Diagnosed Stage IIb/III/IV Hodgkin Lymphoma in Combination with ECADD

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the European Commission (EC) approved ADCETRIS® (brentuximab vedotin) in combination with etoposide, c...

3 months ago - Business Wire

Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera

NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announced detailed results from the Phase...

Other symbols: PTGX
3 months ago - Business Wire

Takeda and Nature Announce Call for Applications Now Open for 2026 Innovators in Science Award

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Applications are now open for the Takeda Innovators in Science Award with Nature recognizing the groundbreaking research of early-career scientists.

3 months ago - Business Wire

The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 1

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE: 4502/NYSE:TAK) today announced that the New England Journal of Medicine published data from the Phase 2b trial of oveporexton (TAK-861) i...

4 months ago - Business Wire

Takeda Pharmaceuticals Caps A Strong Year, Guidance Suggests Dividend Is On The Rise

Takeda Pharmaceuticals showed strong revenue and operating income growth in FY2024, despite challenges from Vyvanse generics and US insurance issues. New guidance for FY2025 is slightly lower due to e...

4 months ago - Seeking Alpha

Takeda Pharmaceutical Company Limited (TAK) Q4 2024 Earnings Call Transcript

Takeda Pharmaceutical Company Limited (NYSE:TAK) Q4 2024 Results Conference Call May 8, 2025 6:00 AM ET Company Participants Christopher O'Reilly - Head, Investor Relations Christophe Weber - Preside...

4 months ago - Seeking Alpha

Takeda Pharma less impacted by tariff, yen headwinds than other Japanese drugmakers: CEO

Christophe Weber, CEO of Takeda Pharma, discusses the group's plans to invest $30 billion into its U.S. operations over the next five years, saying the U.S. market remain crucial for the Japanese drug...

4 months ago - CNBC International TV